RecruitingPhase 1Drug trialSafety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI PatientsThe goal of this study is to evaluate the safety and tolerability of Gamma Glutamylcysteine (GGC) supplement at different doses (400mg/day or 800mg/day or 1200mg/day) when administered orally to patients with MCI over 3 months. This study is designed to generate preliminary clinical safety data to inform the feasibility and design of larger controlled trials.